Changes Of C-Myc, FAK, Her-2, CCND1, And TopoⅡa In Breast Cancer And Their Relationship With Clinicopathologic Parameters

Objective: To study the changes of c-Myc, FAK, Her-2, CCND1, and TopoⅡa in breast cancer and their relationships with clinicopathologic parameters.Methods: Amplification status of c-Myc, FAK, Her-2, CCNB1, and TopoⅡa genes was measured by fluorescence in situ hybridization in fine needle aspiration samples of 84 breast carcinomas, and the expression of the corresponding proteins was measured by immunocytochemistry in 64 of the samples. Correlation analysis was done between the findings and clinicopathologic parameters of the patients (age, status of menstruation, tumor size, histological grading, vascular tumor embolus, status of lymph nodes, ER status, PR status, Her-2 status and stage). Results: The amplification rates of c-Myc, FAK, Her-2, CCND1, and TopoⅡa were 22.6%, 15.5%, 25.0%, 7.1% and 11.9% respectively. Amplification of c-Myc (p:0.009) and Her-2 (p＜0.001) genes correlated with their protein expression respectively. Amplification and overexpression of c-Myc correlated with negative ER (p=0.010, p=0.008). Amplification of FAK gene correlated with more than 3 metastastic lymph nodes (p=O. 035),and overexpression of FAK correlated with positive Her-2 (p=0.005). Amplification of Her-2 gene correlated with positive Her-2 (p＜0.001), and overexpression of Her-2 correlated with negative ER (p=0.007). Amplification of CCND1 gene correlated with histological classification of Grade 1 (p=0.009), and overexpression of Cyclin D1 correlated with tumor size not more than 2 cm (p=0.018). Amplification of ropoⅡa gene correlated with stageⅠ(p=0,038), and overexpression of ropoⅡa correlated with positive Her-2 (p=0.015). Conclusion: There existed correlation between the changes of the five genes and clinicopathologic parameters in breast cancer. Further study should be made to clarify whether these genes can be used as candidate biomarkers for molecular staging and typing in breast cancer.